Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms
Open Access
- 15 May 2026
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (5) , 1094-1102
Abstract
Introduction: RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (m RUNX1 ) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods: Clinical and laboratory data were reviewed for patients with RUNX1 mutations ( N = 125) at Vancouver General Hospital from 2016 to 2022. Diagnostic flow cytometry data were reanalyzed, and RUNX1 mutation characteristics and associations with pathologic, comutation, and flow cytometric features were assessed. Results: Missense RUNX1 mutations (overall 42.9% missense, 57.1% truncating) were enriched in the runt homology domain (RHD; 81.7%, Adj. p = 0.011). Several recurrent hotspot mutations were seen, including common hotspot variants. The most commonly comutated genes with RUNX1 in both acute leukemia with m RUNX1 and MDS‐m RUNX1 were ASXL1 (44.4%; 59.3%), SRSF2 (40.7%; 37.3%), and TET2 (35.8%; 55.9%). The m RUNX1 group demonstrated frequent positivity for B‐lymphoid markers, with 14.4% having increased expression in at least three B‐lineage markers. Differences in antigen expression were associated with RUNX1 mutation type and location, with increased CD10 expression associated with RUNX1 mutations in the RHD (Adj. p = 0.02764), and increased CD79a expression associated with RUNX1 missense mutations (Adj. p = 0.004452). Conclusion: In our cohort, we observed missense variants clustering in the RHD and recurrence of common pathogenic variants. Higher‐risk comutations were found in a substantial fraction of m RUNX1 cases which may contribute to its adverse risk associations. Comparable degrees of aberrancy in B‐lineage markers were seen in m RUNX1 patients versus the comparator cohorts of MPAL‐wt RUNX1 and AML with rearranged RUNX1 .Keywords
Funding Information
- Faculty of Medicine, University of British Columbia (5728)
This publication has 26 references indexed in Scilit:
- Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world studyLeukemia Research, 2024
- Genomic characteristics and prognostic significance of co‐mutatedASXL1/SRSF2acute myeloid leukemiaAmerican Journal of Hematology, 2021
- Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutationHematology, 2020
- Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemiaLeukemia Research Reports, 2018
- The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasiaLeukemia, 2016
- RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresLeukemia, 2016
- Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemiaOncogene, 2004
- Core-binding factors in haematopoiesis and leukaemiaNature Reviews Cancer, 2002
- Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemiaNature Genetics, 1999
- t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.Proceedings of the National Academy of Sciences, 1991